Breaking News

Canada's Consumer Price Index Rises a Less-Than-Forecast 2% in November
Tweet TWEET

Oculus Innovative Sciences Announces Appointment of Sharon Barbari to Its Board of Directors

Oculus Innovative Sciences Announces Appointment of Sharon Barbari to Its
Board of Directors

PETALUMA, Calif., March 27, 2014 (GLOBE NEWSWIRE) -- Oculus Innovative
Sciences, Inc. (Nasdaq:OCLS), today announced the appointment of Sharon
Barbari to its board of directors, effective March 26, 2014.

"We are delighted to have a person of Sharon's caliber join our board. With
her extensive background in corporate finance and health care, she is the
perfect mix of skills, experience and knowledge to help guide our company
forward," stated Jim Schutz, CEO of Oculus. "As we reposition Oculus to
re-ignite our revenue growth, Sharon's expertise will be invaluable."

Ms. Barbari currently serves as executive vice president and CFO for
Cytokinetics, Inc., a clinical-stage biopharmaceutical focused on the
discovery and development of novel small molecule therapeutics that modulate
muscle function for the potential treatment of serious diseases and medical
conditions.Ms. Barbari began her career at Syntex Corporation, an
international pharmaceutical company.She has also served as VP of strategic
planning at Foote, Cone & Belding Healthcare, an international advertising and
marketing firm; vice president and CFO for Gilead Sciences, a
biopharmaceutical company; and CFO and senior vice president of finance and
administration for InterMune, Inc, a biotechnology company.

Ms. Barbari received her B.S. in accounting from San Jose State University.

About Oculus Innovative Sciences

Oculus Innovative Science is a global healthcare company that designs,
manufactures and marketsprescription and non-prescription products in 31
countries. The company's products are used to treat patients in
surgical/advanced wound management, dermatology, women's health and animal
health; addressing the unmet medical needs of these markets, while raising the
standard ofpatient care and lowering overall healthcare costs. The company's
headquarters are in Petaluma, California, with manufacturing operations in the
United States and Latin America. More information can be found
atwww.oculusis.com.

Forward-Looking Statements

Except for historical information herein,matters set forth in this press
release are forward-looking within the meaning of the "safe harbor" provisions
of the Private Securities Litigation Reform Act of 1995, including statements
about the commercial and technology progress and futurefinancial performance
of Oculus Innovative Sciences, Inc. and its subsidiaries (the "Company").
These forward-looking statements are identified by the use of words such as
"anticipates,""believes," "expects," and "intends,"among others.
Forward-looking statements in this press release are subject to certain risks
and uncertainties inherent in the Company's business that could cause actual
results to vary, includingsuchrisks thatregulatory clinical and guideline
developments may change,scientific data may not be sufficient to meet
regulatory standards or receipt of required regulatory clearances or
approvals,clinical results may not be replicated in actual patient
settings,protection offered bythe Company'spatents and patent applications
may be challenged, invalidated or circumvented by its competitors,the
available market fortheCompany'sproducts will not be as large as
expected,the Company'sproducts will not be able to penetrate one or more
targeted markets,revenues will not be sufficient to fund further development
and clinical studies, the Company may not meet itsfuture capital needs, and
its ability to obtain additional funding, as well as uncertainties relative to
varying product formulations and a multitude of diverse regulatory and
marketing requirements in different countries and municipalities, the
uncertainties associated with an initial public offering of a separate public
company, and other risks detailed from time to time in the Company's filings
with the Securities and Exchange Commission including the annual report on
Form 10-K for theyear ended March 31, 2013. Oculus Innovative Sciences
disclaims any obligation to update these forward-looking statements except as
required by law.

Oculus and Microcyn® Technology are trademarks or registered trademarks of
Oculus Innovative Sciences, Inc. All other trademarks and service marks are
the property of their respective owners.

High-resolution photo of Ms. Barbari available upon request.

CONTACT: Media and Investor Contact:
         Oculus Innovative Sciences, Inc.
         Dan McFadden
         Director of Public and Investor Relations
         (425) 753-2105
         dmcfadden@oculusis.com
 
Press spacebar to pause and continue. Press esc to stop.